Cardiol Therapeutics’ Phase II Recurrent Pericarditis Data Published in the Journal of the American Heart Association

Peer-reviewed JAHA publication strengthens the foundation for Cardiol’s pivotal Phase III MAVERIC trial as enrollment nears completion. Toronto, ON, July 14, 2026 – Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) (“Cardiol” or the “Company”), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of its Phase II MAvERIC study results in the Journal of the American Heart Association (“JAHA“). The publication comes as the pivotal Phase III MAVERIC trial nears full patient enrollment. The publication describes clinical findings in which CardiolRx™ was associated with rapid and sustained reductions in pericarditis pain and inflammation in patients with a high baseline disease burden. The study also reported substantial reductions in pericarditis episodes per year and a favorable safety and tolerability profile. Together, these findings provide the strong clinical rationale for MAVERIC, a randomized, double-blind, placebo-controlled, pivotal Phase III trial evaluating CardiolRx™ for reducing the risk of pericarditis recurrence. “The publication of these results in the Journal of the American Heart Association makes the full body of peer-reviewed Phase II evidence available to the broader cardiovascular community,” said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. “The publication provides comprehensive details of findings previously presented at the American Heart Association Scientific Sessions, including clinically important reductions in pain, inflammation, and recurrences with CardiolRx™, a favorable safety and tolerability profile, and its potential to offer a non-immunosuppressive treatment for patients living with recurrent disease. These findings directly informed the design of MAVERIC, our pivotal Phase III study. With enrollment now approaching completion, we believe the strong level of interest highlights the unmet need in this patient population and reinforces our confidence in the potential of CardiolRx™ to advance the standard of care.” The full publication is available in the Journal of the American Heart Association: www.ahajournals.org/doi/full/10.1161/JAHA.125.047605 About Cardiol Therapeutics Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular innate immune system response known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure. The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis. The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis—an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population. The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure—a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year. For more information about Cardiol Therapeutics, please visit cardiolrx.com. Cautionary statement regarding forward-looking information: This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are “forward-looking information”. Forward looking information contained herein may include, but is not limited to statements regarding the Company’s focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company’s intended clinical studies and trial activities and timelines associated with such activities, including the Company’s plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company’s plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure, the JAHA publication strengthens the foundation of the pivotal Phase III program in recurrent pericarditis; and with enrollment in MAVERIC now approaching completion we believe the strong level of interest highlights the unmet need in this patient population and reinforces our confidence in the potential of CardiolRx™ to advance the standard of care. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company’s Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements. For further information, please contact: [email protected] Press Releases Press Release Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™’s EfficacySeptember 23, 2026 Press Release Cardiol Therapeutics Announces Warrant Exercise for Over USD $7 Million in ProceedsSeptember 16, 2026 Press Release Cardiol Therapeutics Files US$150 Million Preliminary Base Shelf Prospectus Including Additional Disclosure Following Review by Staff of the Ontario Securities CommissionSeptember 10, 2026 View all Join our newsletter Sign up to receive the latest news from Cardiol Therapeutics! By subscribing you agree to with our Privacy Policy Name(Required) First Last Email(Required) CAPTCHA Subscribe gform.initializeOnLoaded( function() {jQuery('#gform_ajax_frame_8').on('load',function(){var contents = jQuery(this).contents().find('*').html();var is_postback = contents.indexOf('GF_AJAX_POSTBACK') >= 0;if(!is_postback){return;}var form_content = jQuery(this).contents().find('#gform_wrapper_8');var is_confirmation = jQuery(this).contents().find('#gform_confirmation_wrapper_8').length > 0;var is_redirect = contents.indexOf('gformRedirect(){') >= 0;var is_form = form_content.length > 0 && ! is_redirect && ! is_confirmation;var mt = parseInt(jQuery('html').css('margin-top'), 10) + parseInt(jQuery('body').css('margin-top'), 10) + 100;if(is_form){jQuery('#gform_wrapper_8').html(form_content.html());if(form_content.hasClass('gform_validation_error')){jQuery('#gform_wrapper_8').addClass('gform_validation_error');} else {jQuery('#gform_wrapper_8').removeClass('gform_validation_error');}setTimeout( function() { /* delay the scroll by 50 milliseconds to fix a bug in chrome */ jQuery(document).scrollTop(jQuery('#gform_wrapper_8').offset().top - mt); }, 50 );var current_page = jQuery('#gform_source_page_number_8').val();jQuery(document).trigger('gform_page_loaded', [8, current_page]);window['gf_submitting_8'] = false;}else if(!is_redirect){var confirmation_content = jQuery(this).contents().find('.GF_AJAX_POSTBACK').html();if(!confirmation_content){confirmation_content = contents;}jQuery('#gform_wrapper_8').replaceWith(confirmation_content);jQuery(document).scrollTop(jQuery('#gf_8').offset().top - mt);jQuery(document).trigger('gform_confirmation_loaded', [8]);window['gf_submitting_8'] = false;wp.a11y.speak(jQuery('#gform_confirmation_message_8').text());}else{jQuery('#gform_8').append(contents);if(window['gformRedirect']) {gformRedirect();}}jQuery(document).trigger("gform_pre_post_render", [{ formId: "8", currentPage: "current_page", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_8" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_8"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_8" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 8, current_page ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );} ); Company Company Management Team Board of Directors Scientific Advisory Board Our Advisors Collaborators Our Focus Pericarditis Myocarditis Heart Failure The Inflammasome Pipeline Clinical Trials CardiolRx™ CRD-38 Partnering Insights Blog Community Engagement Resources Investors Events & Presentations Press Releases Analyst Coverage Stock Information Filings & Financials Corporate Governance FAQ Contact Us .cls-1{fill:#fff;} 2026 Cardiol Therapeutics. All right reserved. {"prefetch":[{"source":"document","where":{"and":[{"href_matches":"/*"},{"not":{"href_matches":["/wp-*.php","/wp-admin/*","/wp-content/uploads/*","/wp-content/*","/wp-content/plugins/*","/wp-content/themes/cardiolrebuild/*","/*\\?(.+)"]}},{"not":{"selector_matches":"a[rel~=\"nofollow\"]"}},{"not":{"selector_matches":".no-prefetch, .no-prefetch a"}}]},"eagerness":"conservative"}]} (function(d,s,i,r) { if (d.getElementById(i)){return;} var n=d.createElement(s),e=d.getElementsByTagName(s)[0]; n.id=i;n.src='//js.hs-analytics.net/analytics/'+(Math.ceil(new Date()/r)*r)+'/343442423.js'; e.parentNode.insertBefore(n, e); })(document,"script","hs-analytics",300000); var ajax_obj = {"ajax_url":"https://www.cardiolrx.com/wp-admin/admin-ajax.php","nonce":"447b8c5fac"}; //# sourceURL=functions-js-extra wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); //# sourceURL=wp-i18n-js-after var gform_i18n = {"datepicker":{"wdOffset":1,"helpTextShort":"Press F1 for help","helpText":"Press the arrow keys to navigate by day, PageUp and PageDown to navigate by month, Alt+PageUp and Alt+PageDown to navigate by year, or Escape to cancel.","openOnFocusHelpText":"Press Down arrow to browse the calendar, or Escape to close.","tooltipTxt":"Press Escape to cancel","disabledTxt":"Disabled","markedTxt":"Selected","prevTxt":"Previous","nextTxt":"Next","monthTxt":"Month","yearTxt":"Year","months":["January","February","March","April","May","June","July","August","September","October","November","December"],"days":[{"s":"S","l":"Sunday"},{"s":"M","l":"Monday"},{"s":"T","l":"Tuesday"},{"s":"W","l":"Wednesday"},{"s":"T","l":"Thursday"},{"s":"F","l":"Friday"},{"s":"S","l":"Saturday"}]}}; var gf_legacy_multi = []; var gform_gravityforms = {"strings":{"invalid_file_extension":"This type of file is not allowed. Must be one of the following:","file_uploaded":"File uploaded","delete_file":"Delete this file","in_progress":"in progress","file_exceeds_limit":"File exceeds size limit","illegal_extension":"This type of file is not allowed.","max_reached":"Maximum number of files reached","unknown_error":"There was a problem while saving the file on the server","currently_uploading":"Please wait for the uploading to complete","cancel":"Cancel","cancel_upload":"Cancel this upload","cancelled":"Cancelled","error":"Error","message":"Message"},"vars":{"images_url":"https://www.cardiolrx.com/wp-content/plugins/gravityforms/images"}}; var gf_global = {"gf_currency_config":{"name":"U.S. Dollar","symbol_left":"$","symbol_right":"","symbol_padding":"","thousand_separator":",","decimal_separator":".","decimals":2,"code":"USD"},"base_url":"https://www.cardiolrx.com/wp-content/plugins/gravityforms","number_formats":[],"version_hash":"11bf0287fead25f5ea16c25d10ee1c7b","countries":{"AF":"Afghanistan","AX":"\u00c5land Islands","AL":"Albania","DZ":"Algeria","AS":"American Samoa","AD":"Andorra","AO":"Angola","AI":"Anguilla","AQ":"Antarctica","AG":"Antigua and Barbuda","AR":"Argentina","AM":"Armenia","AW":"Aruba","AU":"Australia","AT":"Austria","AZ":"Azerbaijan","BS":"Bahamas","BH":"Bahrain","BD":"Bangladesh","BB":"Barbados","BY":"Belarus","BE":"Belgium","BZ":"Belize","BJ":"Benin","BM":"Bermuda","BT":"Bhutan","BO":"Bolivia","BQ":"Bonaire, Sint Eustatius and Saba","BA":"Bosnia and Herzegovina","BW":"Botswana","BV":"Bouvet Island","BR":"Brazil","IO":"British Indian Ocean Territory","BN":"Brunei Darussalam","BG":"Bulgaria","BF":"Burkina Faso","BI":"Burundi","CV":"Cabo Verde","KH":"Cambodia","CM":"Cameroon","CA":"Canada","KY":"Cayman Islands","CF":"Central African Republic","TD":"Chad","CL":"Chile","CN":"China","CX":"Christmas Island","CC":"Cocos Islands","CO":"Colombia","KM":"Comoros","CD":"Congo, Democratic Republic of the","CG":"Congo","CK":"Cook Islands","CR":"Costa Rica","CI":"C\u00f4te d'Ivoire","HR":"Croatia","CU":"Cuba","CW":"Cura\u00e7ao","CY":"Cyprus","CZ":"Czechia","DK":"Denmark","DJ":"Djibouti","DM":"Dominica","DO":"Dominican Republic","EC":"Ecuador","EG":"Egypt","SV":"El Salvador","GQ":"Equatorial Guinea","ER":"Eritrea","EE":"Estonia","SZ":"Eswatini","ET":"Ethiopia","FK":"Falkland Islands","FO":"Faroe Islands","FJ":"Fiji","FI":"Finland","FR":"France","GF":"French Guiana","PF":"French Polynesia","TF":"French Southern Territories","GA":"Gabon","GM":"Gambia","GE":"Georgia","DE":"Germany","GH":"Ghana","GI":"Gibraltar","GR":"Greece","GL":"Greenland","GD":"Grenada","GP":"Guadeloupe","GU":"Guam","GT":"Guatemala","GG":"Guernsey","GN":"Guinea","GW":"Guinea-Bissau","GY":"Guyana","HT":"Haiti","HM":"Heard Island and McDonald Islands","VA":"Holy See","HN":"Honduras","HK":"Hong Kong","HU":"Hungary","IS":"Iceland","IN":"India","ID":"Indonesia","IR":"Iran","IQ":"Iraq","IE":"Ireland","IM":"Isle of Man","IL":"Israel","IT":"Italy","JM":"Jamaica","JP":"Japan","JE":"Jersey","JO":"Jordan","KZ":"Kazakhstan","KE":"Kenya","KI":"Kiribati","KP":"Korea, Democratic People's Republic of","KR":"Korea, Republic of","KW":"Kuwait","KG":"Kyrgyzstan","LA":"Lao People's Democratic Republic","LV":"Latvia","LB":"Lebanon","LS":"Lesotho","LR":"Liberia","LY":"Libya","LI":"Liechtenstein","LT":"Lithuania","LU":"Luxembourg","MO":"Macao","MG":"Madagascar","MW":"Malawi","MY":"Malaysia","MV":"Maldives","ML":"Mali","MT":"Malta","MH":"Marshall Islands","MQ":"Martinique","MR":"Mauritania","MU":"Mauritius","YT":"Mayotte","MX":"Mexico","FM":"Micronesia","MD":"Moldova","MC":"Monaco","MN":"Mongolia","ME":"Montenegro","MS":"Montserrat","MA":"Morocco","MZ":"Mozambique","MM":"Myanmar","NA":"Namibia","NR":"Nauru","NP":"Nepal","NL":"Netherlands","NC":"New Caledonia","NZ":"New Zealand","NI":"Nicaragua","NE":"Niger","NG":"Nigeria","NU":"Niue","NF":"Norfolk Island","MK":"North Macedonia","MP":"Northern Mariana Islands","NO":"Norway","OM":"Oman","PK":"Pakistan","PW":"Palau","PS":"Palestine, State of","PA":"Panama","PG":"Papua New Guinea","PY":"Paraguay","PE":"Peru","PH":"Philippines","PN":"Pitcairn","PL":"Poland","PT":"Portugal","PR":"Puerto Rico","QA":"Qatar","RE":"R\u00e9union","RO":"Romania","RU":"Russian Federation","RW":"Rwanda","BL":"Saint Barth\u00e9lemy","SH":"Saint Helena, Ascension and Tristan da Cunha","KN":"Saint Kitts and Nevis","LC":"Saint Lucia","MF":"Saint Martin","PM":"Saint Pierre and Miquelon","VC":"Saint Vincent and the Grenadines","WS":"Samoa","SM":"San Marino","ST":"Sao Tome and Principe","SA":"Saudi Arabia","SN":"Senegal","RS":"Serbia","SC":"Seychelles","SL":"Sierra Leone","SG":"Singapore","SX":"Sint Maarten","SK":"Slovakia","SI":"Slovenia","SB":"Solomon Islands","SO":"Somalia","ZA":"South Africa","GS":"South Georgia and the South Sandwich Islands","SS":"South Sudan","ES":"Spain","LK":"Sri Lanka","SD":"Sudan","SR":"Suriname","SJ":"Svalbard and Jan Mayen","SE":"Sweden","CH":"Switzerland","SY":"Syria Arab Republic","TW":"Taiwan","TJ":"Tajikistan","TZ":"Tanzania, the United Republic of","TH":"Thailand","TL":"Timor-Leste","TG":"Togo","TK":"Tokelau","TO":"Tonga","TT":"Trinidad and Tobago","TN":"Tunisia","TR":"T\u00fcrkiye","TM":"Turkmenistan","TC":"Turks and Caicos Islands","TV":"Tuvalu","UG":"Uganda","UA":"Ukraine","AE":"United Arab Emirates","GB":"United Kingdom","US":"United States","UY":"Uruguay","UM":"US Minor Outlying Islands","UZ":"Uzbekistan","VU":"Vanuatu","VE":"Venezuela","VN":"Viet Nam","VG":"Virgin Islands, British","VI":"Virgin Islands, U.S.","WF":"Wallis and Futuna","EH":"Western Sahara","YE":"Yemen","ZM":"Zambia","ZW":"Zimbabwe"},"strings":{"newRowAdded":"New row added.","rowRemoved":"Row removed","formSaved":"The form has been saved. The content contains the link to return and complete the form."}}; //# sourceURL=gform_gravityforms-js-extra var gform_theme_config = {"common":{"form":{"honeypot":{"version_hash":"11bf0287fead25f5ea16c25d10ee1c7b"},"ajax":{"ajaxurl":"https://www.cardiolrx.com/wp-admin/admin-ajax.php","ajax_submission_nonce":"ab128c5cf7","i18n":{"step_announcement":"Step %1$s of %2$s, %3$s","unknown_error":"There was an unknown error processing your request. Please try again.","error_403":"The request was blocked (403 error) for unknown security reasons. Remove any code-like text (scripts or DB queries) and try again."}}}},"hmr_dev":"","public_path":"https://www.cardiolrx.com/wp-content/plugins/gravityforms/assets/js/dist/","config_nonce":"249d5c3145"}; //# sourceURL=gform_gravityforms_theme-js-extra {"baseUrl":"https://s.w.org/images/core/emoji/17.0.2/72x72/","ext":".png","svgUrl":"https://s.w.org/images/core/emoji/17.0.2/svg/","svgExt":".svg","source":{"concatemoji":"https://www.cardiolrx.com/wp-includes/js/wp-emoji-release.min.js?ver=7.1.2"}} /*! This file is auto-generated */ var e="script#wp-emoji-settings",t=document.querySelector(e);if(!(t instanceof HTMLScriptElement))throw new Error("Element missing: "+e);const r=JSON.parse(t.text),s=(window._wpemojiSettings=r,"wpEmojiSettingsSupports"),o=["flag","emoji"];function i(e){try{var t={supportTests:e,timestamp:(new Date).valueOf()};sessionStorage.setItem(s,JSON.stringify(t))}catch(e){}}function c(e,t,n){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);t=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data);e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(n,0,0);const r=new Uint32Array(e.getImageData(0,0,e.canvas.width,e.canvas.height).data);return t.every((e,t)=>e===r[t])}function p(e,t){e.clearRect(0,0,e.canvas.width,e.canvas.height),e.fillText(t,0,0);var n=e.getImageData(16,16,1,1);for(let e=0;e<n.data.length;e++)if(0!==n.data[e])return!1;return!0}function u(e,t,n,r){switch(t){case"flag":return n(e,"\ud83c\udff3\ufe0f\u200d\u26a7\ufe0f","\ud83c\udff3\ufe0f\u200b\u26a7\ufe0f")?!1:!n(e,"\ud83c\udde8\ud83c\uddf6","\ud83c\udde8\u200b\ud83c\uddf6")&&!n(e,"\ud83c\udff4\udb40\udc67\udb40\udc62\udb40\udc65\udb40\udc6e\udb40\udc67\udb40\udc7f","\ud83c\udff4\u200b\udb40\udc67\u200b\udb40\udc62\u200b\udb40\udc65\u200b\udb40\udc6e\u200b\udb40\udc67\u200b\udb40\udc7f");case"emoji":return!r(e,"\ud83e\u1fac8")}return!1}function f(e,t,n,r){let a;const s=(a="undefined"!=typeof WorkerGlobalScope&&self instanceof WorkerGlobalScope?new OffscreenCanvas(300,150):document.createElement("canvas")).getContext("2d",{willReadFrequently:!0}),o=(s.textBaseline="top",s.font="600 32px Arial",{});return e.forEach(e=>{o[e]=t(s,e,n,r)}),o}function a(e){var t=document.createElement("script");t.src=e,t.defer=!0,document.head.appendChild(t)}r.supports={everything:!0,everythingExceptFlag:!0},new Promise(t=>{let n=function(){try{var e=JSON.parse(sessionStorage.getItem(s));if("object"==typeof e&&"number"==typeof e.timestamp&&(new Date).valueOf()<e.timestamp+604800&&"object"==typeof e.supportTests)return e.supportTests}catch(e){}return null}();if(!n){if("undefined"!=typeof Worker&&"undefined"!=typeof OffscreenCanvas&&"undefined"!=typeof URL&&URL.createObjectURL&&"undefined"!=typeof Blob)try{var e="postMessage("+f.toString()+"("+[JSON.stringify(o),u.toString(),c.toString(),p.toString()].join(",")+"));",r=new Blob([e],{type:"text/javascript"});const a=new Worker(URL.createObjectURL(r),{name:"wpTestEmojiSupports"});return void(a.onmessage=e=>{i(n=e.data),a.terminate(),t(n)})}catch(e){}i(n=f(o,u,c,p))}t(n)}).then(e=>{for(const n in e)r.supports[n]=e[n],r.supports.everything=r.supports.everything&&r.supports[n],"flag"!==n&&(r.supports.everythingExceptFlag=r.supports.everythingExceptFlag&&r.supports[n]);var t;r.supports.everythingExceptFlag=r.supports.everythingExceptFlag&&!r.supports.flag,r.supports.everything||((t=r.source||{}).concatemoji?a(t.concatemoji):t.wpemoji&&t.twemoji&&(a(t.twemoji),a(t.wpemoji)))}); //# sourceURL=https://www.cardiolrx.com/wp-includes/js/wp-emoji-loader.min.js gform.initializeOnLoaded( function() { jQuery(document).on('gform_post_render', function(event, formId, currentPage){if(formId == 8) {if(typeof Placeholders != 'undefined'){ Placeholders.enable(); }} } );jQuery(document).on('gform_post_conditional_logic', function(event, formId, fields, isInit){} ) } ); gform.initializeOnLoaded( function() {jQuery(document).trigger("gform_pre_post_render", [{ formId: "8", currentPage: "1", abort: function() { this.preventDefault(); } }]); if (event && event.defaultPrevented) { return; } const gformWrapperDiv = document.getElementById( "gform_wrapper_8" ); if ( gformWrapperDiv ) { const visibilitySpan = document.createElement( "span" ); visibilitySpan.id = "gform_visibility_test_8"; gformWrapperDiv.insertAdjacentElement( "afterend", visibilitySpan ); } const visibilityTestDiv = document.getElementById( "gform_visibility_test_8" ); let postRenderFired = false; function triggerPostRender() { if ( postRenderFired ) { return; } postRenderFired = true; gform.core.triggerPostRenderEvents( 8, 1 ); if ( visibilityTestDiv ) { visibilityTestDiv.parentNode.removeChild( visibilityTestDiv ); } } function debounce( func, wait, immediate ) { var timeout; return function() { var context = this, args = arguments; var later = function() { timeout = null; if ( !immediate ) func.apply( context, args ); }; var callNow = immediate && !timeout; clearTimeout( timeout ); timeout = setTimeout( later, wait ); if ( callNow ) func.apply( context, args ); }; } const debouncedTriggerPostRender = debounce( function() { triggerPostRender(); }, 200 ); if ( visibilityTestDiv && visibilityTestDiv.offsetParent === null ) { const observer = new MutationObserver( ( mutations ) => { mutations.forEach( ( mutation ) => { if ( mutation.type === 'attributes' && visibilityTestDiv.offsetParent !== null ) { debouncedTriggerPostRender(); observer.disconnect(); } }); }); observer.observe( document.body, { attributes: true, childList: false, subtree: true, attributeFilter: [ 'style', 'class' ], }); } else { triggerPostRender(); } } );

The release as fetched from its publisher. cardiolrx.com ↗